Spots Global Cancer Trial Database for pegylated liposomal doxorubicin (pld)
Every month we try and update this database with for pegylated liposomal doxorubicin (pld) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | NCT01121406 | Ovarian Neoplas... | Paclitaxel Gemcitabine Topotecan Pegylated lipos... BI 6727 | 18 Years - | Boehringer Ingelheim | |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | NCT00722592 | Ovarian Cancer | Vintafolide pegylated lipos... EC20 | 18 Years - | Endocyte | |
| Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | NCT05159193 | Breast Cancer | pegylated lipos... cyclophosphamid... trastuzumab (H) pertuzumab (P) docetaxel (T) docetaxel (T) carboplatin (Cb... trastuzumab (H) pertuzumab (P) | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer | NCT04101812 | Muscle Invasive... | pegylated lipos... PD-1 | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | NCT02865811 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Pembrolizumab Pegylated Lipos... | 18 Years - | Dana-Farber Cancer Institute | |
| Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | NCT02421588 | Ovarian Cancer | Lurbinectedin (... Pegylated lipos... Topotecan | 18 Years - | PharmaMar | |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | NCT00722592 | Ovarian Cancer | Vintafolide pegylated lipos... EC20 | 18 Years - | Endocyte | |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | NCT04244552 | Breast Cancer Colorectal Canc... Ovarian Cancer Non-Small Cell ... Acral Lentigino... Head and Neck S... Hepatocellular ... Esophageal Squa... Urothelial Carc... DMMR Colorectal... MSI-H Colorecta... Melanoma Platinum-Resist... Platinum-Resist... Platinum-Resist... Triple Negative... | ATRC-101 Pembrolizumab Pegylated lipos... | 18 Years - | Atreca, Inc. | |
| Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | NCT03639246 | Ovarian Cancer | AVB-S6-500 Paclitaxel (Pac... Pegylated lipos... Placebo | 18 Years - | Aravive, Inc. | |
| BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | NCT01121406 | Ovarian Neoplas... | Paclitaxel Gemcitabine Topotecan Pegylated lipos... BI 6727 | 18 Years - | Boehringer Ingelheim | |
| Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | NCT01541332 | Multiple Myelom... | Pomalidomide Pegylated Lipos... Dexamethasone | 18 Years - | Oncotherapeutics | |
| A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | NCT01016054 | Carcinoma Ovarian Cancer Ovarian Disease... Ovarian Neoplas... | AGS-8M4 Pegylated lipos... gemcitabine carboplatin | 18 Years - | Astellas Pharma Inc | |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01666444 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | pegylated lipos... VTX-2337 Placebo | 18 Years - | Celgene | |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | NCT03719326 | TNBC - Triple-N... Ovarian Cancer | Etrumadenant IPI-549 Pegylated lipos... nanoparticle al... | 18 Years - | Arcus Biosciences, Inc. | |
| Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer | NCT04274426 | Recurrent Epith... | Carboplatin Pegylated lipos... Gemcitabine Paclitaxel Mirvetuximab So... | 18 Years - | AGO Research GmbH | |
| Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | NCT02866370 | Ovarian Clear C... Endometrial Cle... | Nintedanib Paclitaxel Pegylated Lipos... Topotecan Carboplatin Doxorubicin | 18 Years - | NHS Greater Glasgow and Clyde | |
| Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer | NCT03598270 | Recurrent Ovari... | Placebo Carboplatin Paclitaxel Niraparib Gemcitabine Pegylated lipos... Atezolizumab | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario | |
| A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT05613088 | Neoplasms, Ovar... | MORAb-202 Paclitaxel Pegylated Lipos... Topotecan | 18 Years - | Bristol-Myers Squibb | |
| Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | NCT02584478 | Endometrial Car... Ovarian Carcino... Fallopian Tube ... Primary Periton... Cervical Carcin... | AL3818 Paclitaxel Pegylated Lipos... Topotecan Topotecan Carboplatin Paclitaxel AL3818 | 18 Years - | Advenchen Laboratories, LLC | |
| Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | NCT02866370 | Ovarian Clear C... Endometrial Cle... | Nintedanib Paclitaxel Pegylated Lipos... Topotecan Carboplatin Doxorubicin | 18 Years - | NHS Greater Glasgow and Clyde | |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01666444 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | pegylated lipos... VTX-2337 Placebo | 18 Years - | Celgene | |
| Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | NCT02865811 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Pembrolizumab Pegylated Lipos... | 18 Years - | Dana-Farber Cancer Institute | |
| Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer | NCT03598270 | Recurrent Ovari... | Placebo Carboplatin Paclitaxel Niraparib Gemcitabine Pegylated lipos... Atezolizumab | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
